A country guide to clinical trials in France; oncology leadership, ANSM review pathways, CHU networks, patient access, and the national push to lead European clinical research.
France is the second largest country in the EU by area and the third most populous with 68 million people. It is one of only two countries besides the United States to feature in the world's top ten medical research organizations; with INSERM and AP-HP both holding that distinction. France's centralized healthcare system (Sécurité Sociale) covers nearly the entire population and is structured around a network of CHUs (Centres Hospitaliers Universitaires) spread across every region, giving France an unusually geographically distributed research infrastructure compared to countries where activity concentrates in one or two cities.
By Q3 2023, France ranked first in Europe on ClinicalTrials.gov with 34,380 studies featuring French sites. The government's Health Innovation 2030 plan has set an explicit national goal: make France the leading country in Europe for clinical trials. Investment is flowing into regulatory streamlining, a national clinical trials database, and expansion of early-phase capabilities through the CLIP² network of Phase précoce centers.
France's 68 million people are among Europe's most diverse; reflecting centuries of immigration from North Africa (Algeria, Morocco, Tunisia), Sub-Saharan Africa, Southern Europe, and Southeast Asia. This diversity is a meaningful asset for sponsors seeking demographic breadth within a Western European regulatory environment. The population has a mature age structure (median age ~42) with strong representation of older cohorts driving oncology, cardiovascular, and neurodegenerative disease research demand.
France's universal Sécurité Sociale system provides structured access to a patient population that is well-documented, medically engaged, and distributed across a national CHU network. More than 15% of patients treated at France's 18 Cancer Centers (CLCC) are enrolled in a clinical trial; one of the highest participation rates in the world. The country's average time to first patient has improved from 204 days (2019) to 182 days (2021), with further reductions expected under the 2026 fast-track framework.
Oncology depth: Oncology accounts for 40–45% of all clinical trials conducted in France; the highest concentration in Europe. France ranks second in Europe and fourth globally for oncology trial participation, and second in Europe specifically for early-stage oncology trials. Gustave Roussy's DITEP unit is the world's #1 Phase I oncology department.
France's competitive advantage is the combination of population scale (68M), oncology depth (Gustave Roussy, Institut Curie, 18 CLCC Cancer Centers, AP-HP's 30+ university hospitals), and a government actively investing to make the country more attractive. ANSM's standard review is 31 days; already competitive with most EU peers. From Q1 2026, a new fast-track pathway cuts this to 14 days (no questions) or 49 days (with questions) for early-phase, rare disease, first-in-class, and adolescent trials. INSERM and AP-HP together form one of the world's most prolific academic clinical research machines.
Gustave Roussy; Europe's #1 cancer center, world #6. DITEP; world's #1 Phase I oncology unit. 40% of patients at CLCC centers enrolled in trials. 18 Cancer Centers nationally. Institut Curie, Centre Léon Bérard, IUCT Oncopole; all world-class.
Standard ANSM review: 31 days. Fast-track from Q1 2026: 14 days (no questions) for early-phase, rare disease, first-in-class, and adolescent trials. Average time to first patient: 182 days (down from 204 in 2019) and falling.
INSERM (top-10 global medical research); AP-HP (30+ university hospitals, 1,500+ ongoing studies); 59,150 scientific publications in a decade; only country besides the US in the world's top 10 medical research organizations; twice over.
CHU network across all 13 regions; AP-HP managing 30+ Paris hospitals; 18 CLCC Cancer Centers (Unicancer network); national CLIP² early-phase oncology center accreditation; government Health Innovation 2030 plan with national digital trials database underway.
Oncology is France's defining clinical research strength; 40–45% of all French trials, second in Europe and fourth globally. France leads Europe in advanced therapy medicinal products (ATMPs) regulation and expertise, and is second in Europe for early-phase oncology trials. Rare diseases are France's second pillar, driven by Orphanet (the world's rare disease database, coordinated from Paris), the national rare disease plan, and specialist centers across the CHU network. Neuroscience, infectious disease, and cardiology round out the top research areas. The Necker-Enfants Malades Hospital makes France a global leader in pediatric rare disease research.
France's trial activity concentrates in Paris and its Île-de-France region (Gustave Roussy, AP-HP, Institut Curie) but the CHU and CLCC Cancer Center networks ensure meaningful national distribution across Lyon, Marseille, Bordeaux, Lille, Rennes, Toulouse, and beyond.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Institut Gustave Roussy; DITEP | Villejuif (Paris) | Europe's largest cancer center and #6 globally (Newsweek); 54,300+ patients/year; 40% enrolled in clinical trials; 7,505 patients in studies annually; DITEP is the world's #1 Phase I oncology unit (CLIP² accredited); 1,400 scientific publications/year; 300+ active trials; leading in immunotherapy, precision medicine, and molecular profiling. |
| 02 | AP-HP; Assistance Publique–Hôpitaux de Paris | Paris (30+ hospitals) | Manages 30+ university hospitals across Greater Paris; 1,500+ ongoing clinical studies; DRCI clinical research infrastructure; EDS data warehouse for real-time patient feasibility; top global medical research organization alongside INSERM; covers every therapeutic area across Bichat, Pitié-Salpêtrière, Hôtel-Dieu, and more. |
| 03 | Institut Curie | Paris / Saint-Cloud | Comprehensive cancer center; Unicancer member; Phase I–III oncology specialist; proton therapy center; breast, gynecological, and pediatric oncology excellence; retinoblastoma international reference; Paris campus + Saint-Cloud site. |
| 04 | Hôpital Necker-Enfants Malades (AP-HP) | Paris | France's and Europe's leading pediatric hospital; rare disease and gene therapy specialist; pediatric oncology (CANPEDIF network with Gustave Roussy and Curie); hematology and immunodeficiency trials; Phase I–III pediatric capability. |
| 05 | Centre Léon Bérard (CLB) | Lyon | Unicancer comprehensive cancer center; Lyon's primary oncology research site; Unicancer network coordination; proton therapy research (PROTECT ESMO trial); Phase I early-phase program; Centre de Recherche en Cancérologie de Lyon (CRCL). |
| 06 | IUCT Oncopole; Institut Universitaire du Cancer Toulouse | Toulouse | One of Europe's largest cancer campuses; Unicancer member; Phase I–III oncology across hematology, solid tumors, and rare cancers; co-located with CHU Toulouse ensuring broad therapeutic area coverage. |
| 07 | CHU de Bordeaux; Hôpital Haut-Lévêque | Bordeaux | Major southwest France academic medical center; cardiology, oncology, and neurology trials; Bordeaux University Hospital research infrastructure; Phase II–IV commercial trial participant. |
| 08 | CHU de Lille | Lille | Northern France's flagship academic medical center; one of France's largest CHUs; oncology, hematology, infectious disease, and metabolic research; major Phase II–IV portfolio; strong industry-academic collaboration. |
| 09 | Institut Paoli-Calmettes | Marseille | Unicancer comprehensive cancer center; bone marrow transplantation and hematology leader; Mediterranean oncology patient population; Phase I–III trials; Aix-Marseille University affiliation. |
| 10 | CHU de Rennes; Hôpital Pontchaillou | Rennes | Brittany's primary academic medical center; oncology, infectious disease, and cardiovascular trials; INSERM-affiliated research units; Phase II–IV participation in multinational studies. |
| 11 | Hôpital Henri Mondor (AP-HP) | Créteil (Paris region) | AP-HP university hospital; hematology, cardiology, and oncology strength; major Phase II–IV trial site; APHP Research Clinical Investigation Center; Paris region cancer and cardiovascular research. |
| 12 | Centre François Baclesse | Caen | Unicancer cancer center; proton therapy center; collaborative leader in radiotherapy innovation trials (PROTECT and related programs); Normandy cancer research hub. |
| 13 | Institut de Cancérologie de Lorraine (ICL) | Nancy | Unicancer comprehensive cancer center; Eastern France oncology hub; Phase I–III trials across solid tumors and hematology; strong integration with University of Lorraine. |
| 14 | CHU de Montpellier; Hôpital Saint-Éloi | Montpellier | Major southern France academic center; oncology, hepatology, and infectious disease trials; INSERM-affiliated research units; clinical investigation center (CIC) for early-phase research. |
| 15 | Institut de Cancérologie de l'Ouest (ICO) | Nantes / Angers | Unicancer cancer center with two sites; breast cancer, sarcoma, and digestive oncology specialist; proton therapy research partner; Phase I–III portfolio spanning solid tumors and rare cancers. |
Europe's largest cancer center and #6 globally (Newsweek); 54,300+ patients/year; 40% enrolled in clinical trials; 7,505 patients in studies annually; DITEP is the world's #1 Phase I oncology unit (CLIP² accredited); 1,400 scientific publications/year; 300+ active trials; leading in immunotherapy, precision medicine, and molecular profiling.
Manages 30+ university hospitals across Greater Paris; 1,500+ ongoing clinical studies; DRCI clinical research infrastructure; EDS data warehouse for real-time patient feasibility; top global medical research organization alongside INSERM; covers every therapeutic area across Bichat, Pitié-Salpêtrière, Hôtel-Dieu, and more.
Comprehensive cancer center; Unicancer member; Phase I–III oncology specialist; proton therapy center; breast, gynecological, and pediatric oncology excellence; retinoblastoma international reference; Paris campus + Saint-Cloud site.
France's and Europe's leading pediatric hospital; rare disease and gene therapy specialist; pediatric oncology (CANPEDIF network with Gustave Roussy and Curie); hematology and immunodeficiency trials; Phase I–III pediatric capability.
Unicancer comprehensive cancer center; Lyon's primary oncology research site; Unicancer network coordination; proton therapy research (PROTECT ESMO trial); Phase I early-phase program; Centre de Recherche en Cancérologie de Lyon (CRCL).
One of Europe's largest cancer campuses; Unicancer member; Phase I–III oncology across hematology, solid tumors, and rare cancers; co-located with CHU Toulouse ensuring broad therapeutic area coverage.
Major southwest France academic medical center; cardiology, oncology, and neurology trials; Bordeaux University Hospital research infrastructure; Phase II–IV commercial trial participant.
Northern France's flagship academic medical center; one of France's largest CHUs; oncology, hematology, infectious disease, and metabolic research; major Phase II–IV portfolio; strong industry-academic collaboration.
Unicancer comprehensive cancer center; bone marrow transplantation and hematology leader; Mediterranean oncology patient population; Phase I–III trials; Aix-Marseille University affiliation.
Brittany's primary academic medical center; oncology, infectious disease, and cardiovascular trials; INSERM-affiliated research units; Phase II–IV participation in multinational studies.
AP-HP university hospital; hematology, cardiology, and oncology strength; major Phase II–IV trial site; APHP Research Clinical Investigation Center; Paris region cancer and cardiovascular research.
Unicancer cancer center; proton therapy center; collaborative leader in radiotherapy innovation trials (PROTECT and related programs); Normandy cancer research hub.
Unicancer comprehensive cancer center; Eastern France oncology hub; Phase I–III trials across solid tumors and hematology; strong integration with University of Lorraine.
Major southern France academic center; oncology, hepatology, and infectious disease trials; INSERM-affiliated research units; clinical investigation center (CIC) for early-phase research.
Unicancer cancer center with two sites; breast cancer, sarcoma, and digestive oncology specialist; proton therapy research partner; Phase I–III portfolio spanning solid tumors and rare cancers.
These are the primary regulatory, academic, and industry bodies shaping France's clinical research ecosystem.
National competent authority; 31-day standard review; fast-track from Q1 2026 (14 days/no questions for eligible trials); Early Trials Unit established 2017; EU CTIS national contact point; governs the CLIP² early-phase center accreditation network.
Oversees Health Innovation 2030 plan; national target to make France Europe's #1 clinical trial country; national clinical trials database development; digital health delegation (DNS) coordinating recruitment tools.
France's research ethics committees; parallel review with ANSM; harmonized national review process under EU CTR; single CPP system for multi-site French trials.
One of the world's top 10 medical research organizations; primary academic clinical research funder; embedded in CHU and CLCC networks; 59,150 publications in a decade; 24% publication growth 2010–2019.
Europe's largest cancer center (#6 world); DITEP = world's #1 Phase I oncology unit; 40% of patients in clinical trials; 7,505 patients enrolled in studies annually; precision medicine, immunotherapy, and molecular profiling leader.
Umbrella organization for France's 18 Cancer Centers (CLCC); 15%+ of patients in trials; coordinates national oncology research strategy; Gustave Roussy, Institut Curie, Centre Léon Bérard, and 15 more CLCCs.
World's largest university hospital group; 1,500+ ongoing studies; EDS data warehouse for real-time feasibility; DRCI clinical research management infrastructure; top-10 global medical research organization.
French pharmaceutical industry association; annual survey on clinical research competitiveness; advocacy for regulatory streamlining; coordinates industry-government dialogue on Health Innovation 2030.
French CRO industry body; represents clinical research organizations conducting trials in France; promotes France's clinical trial competitiveness internationally.
Global CRO with major French operations; supports AP-HP, CLCC, and CHU network trial management; data management, regulatory affairs, and monitoring across Phase I–IV.
Global CRO with Paris-area operations; oncology, rare disease, and CNS focus; ANSM regulatory expertise; EU CTIS submission management.
France is Europe's oncology research capital; full stop. Gustave Roussy's DITEP is the world's #1 Phase I oncology unit. France ranks second in Europe overall and fourth globally for oncology trial participation, with 40–45% of all French trials in cancer. Beyond oncology, it is first in Europe by ClinicalTrials.gov registrations (34,380 studies), home to one of the world's top two medical research organizations (INSERM), and operating one of the most geographically distributed university hospital networks in Europe through the CHU and CLCC systems. The government has made clinical research a national strategic priority under Health Innovation 2030, and ANSM's new fast-track pathway (14 days for eligible trials from Q1 2026) is the most significant regulatory improvement France has introduced in a decade. For oncology, rare diseases, advanced therapies, and any trial needing both scientific credibility and a large, diverse Western European patient population; France belongs on every shortlist.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.